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TREK2 (KCNK10, K2P10.1) is a two-pore domain potassium (K2P) channel and a potential target for the
treatment of pain. Like the majority of the K2P superfamily, there is currently a lack of useful pharma-
cological tools to study TREK2. Here we present a strategy for identifying novel TREK2 activators. A cell-
based thallium ﬂux assay was developed and used to screen a library of drug-like molecules, from which
we identiﬁed the CysLT1 antagonist Pranlukast as a novel activator of TREK2. This compound was se-
lective for TREK2 versus TREK1 and showed no activity at TRAAK. Pranlukast was also screened against
other members of the K2P superfamily. Several close analogues of Pranlukast and other CysLT1 antag-
onists were also tested for their ability to activate K2P channels. Consistent with previous work, structure
activity relationships showed that subtle structural changes to these analogues completely attenuated
the activation of TREK2, whereas for TREK1, analogues moved from activators to inhibitors. Pranlukast’s
activity was also conﬁrmed using whole-cell patch clamp electrophysiology. Studies using mutant forms
of TREK2 suggest Pranlukast does not bind in the K2P modulator pocket or the BL-1249 binding site.
Pranlukast therefore represents a novel tool by which to study the mechanism of TREK2 activation.
© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The KCNK gene family of two-pore domain potassium (K2P)
channels contribute to background (or ‘leak’) potassium current,
helping to establish and maintain resting membrane potential. The
KCNK superfamily comprises 15 channels, which are further sub-
divided into six subfamilies: TREK, TASK, TALK, THIK, TWIK and
TRESK [1]. Each K2P subunit contains two pore-forming loops
which come together to form an active dimer. Functional and ge-
netic evidence has implicated K2Ps in a diverse set of pathophysi-
ologies [2]. Furthermore, K2P channels have been shown to be
expressed in sensory neurons, making them potential targets for
the treatment of pain by using small molecules to increase channel
activity and reduce neuronal excitability [3].
The TREK subfamily (TWIK related Kþ channel) comprises 3
members; TREK1 (KCNK2, K2P2.1), TREK2 (KCNK10, K2P10.1) andht).
r Inc. This is an open access article
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unications, https://doi.org/1TRAAK (KCNK4, K2P4.1). TREK2 and TREK1 share 79% sequence
homology with each other, whereas TRAAK exhibits around 69%
homology with the other TREK channels and exhibits different
characteristics [4]. It has been shown in heterologous expressions
systems that these channels can also form heterodimers with each
other [4]. TREK channels are mechanosensitive [5] and are regu-
lated by both temperature and pH [6]. All members of the TREK
subfamily have also been shown to be expressed in rodent and
human dorsal root ganglion (DRG) cells [7,8] and, combined with
their potential role modulating neuronal excitability, have there-
fore been suggested as novel targets for the treatment of pain [3].
TREK2 has been shown to be selectively expressed on rat IB4þ
C-nociceptors [9]. siRNA knockdown suggests that TREK2 is
responsible for a 10mV hyperpolarization in these cells. In both
small and medium sized rodent DRG neurons TREK2 was also
shown to likely contributemost (69%) to the resting Kþ current [10].
This was shown to be greater than TRESK, TREK1 and TRAAK,
despite the suggestion that TREK2 is expressed at lower levels in
the DRG than TRESK and TRAAK [11]. Importantly, after CFA-
induced inﬂammation, spontaneous foot lifting, a measure ofunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
olecule activator of the two-pore domain potassium channel TREK2,
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lowered by siRNA and in animals with naturally lower levels of
TREK2 [9]. In chronic constriction injury models of neuropathic
pain, an increase in TREK2 mRNA was also observed compared to
non-injured animals [12].
There is overall a lack of speciﬁc pharmacological tools to probe
endogenous K2P channel function and TREK2 is equally under-
served. Several TREK1 activators show activity at TREK2 including
arachidonic acid, docosahexaenoic and linoleic acids, lysophos-
phatidylcholine [13], Flufenamic acid (FFA) [14], BL-1249 [15,16],
ML67-33 [17], ML335 and ML402 [18] and GI-530159 [19].
Screening of a bioactive lipid library identiﬁed 11-deoxy prosta-
glandin F2a as an activator of TREK2 but an inhibitor of TREK1 [20].
This compound was also shown to reduce Ca2þ inﬂux in C-ﬁber
primary DRG cells [20].
Here we describe the development of a thallium based TREK2
assay to facilitate the discovery of channel activators, which led to
the discovery of Pranlukast, a leukotriene receptor antagonist, as a
relatively selective TREK2 activator. Pranlukast’s activity was
conﬁrmed in whole-cell patch clamp electrophysiology and a
subset of Pranlukast analogues were also screened for activity on
K2P channels.2. Materials and methods
2.1. Thallium ﬂux assays
Cells transiently expressing TREK2 (NP_612191, NM_138318.2)
were generated by using U-2 OS cells and TREK2 BacMam (2% v/v)
solution (SB Drug Discovery, UK). For methods detailing thallium
ﬂux assays see Ref. [21]. Channel activity was deﬁned as the in-
crease in ﬂuorescence over baseline between 13 and 19 s, after
thallium addition. For selectivity assays also see Ref. [21].2.2. Whole-cell patch clamp electrophysiology
Most of the methods used here have been described previously
[15,22]. pcDNA3.1 was cloned with the gene of interest. To generate
N-terminally truncated mutants a deletion mutagenesis strategy
was utilized. All constructs, along with a green ﬂuorescent protein
(GFP) expressing vector, were transiently transfected into
tsA201 cells using the calcium phosphate method and used for
experimentation the next day. Currents were recorded using
whole-cell patch clamp in the voltage clamp conﬁguration in an
external solution containing (in mM): 145 NaCl, 2.5 KCl, 3 MgCl2, 1
CaCl2, and 10 HEPES (pH 7.4 using NaOH) and internal solution
containing (in mM): 150 KCl, 3 MgCl2, 5 EGTA, and 10 HEPES (pH 7.4
using KOH). External solutions and compounds were superfused at
a rate of 4e5mLmin1. Complete exchange of solution occurred
within 100e120 s. Patch clamp glass pipettes were pulled from thin
walled borosilicate glass (GC150TF; Harvard Apparatus, Eden-
bridge, UK) and the resistance was measured between 3 and 6MU.
K2P currents were studied using a step-ramp voltage protocol
starting at a holding potential of 60 mV . The cells were then
hyperpolarised from 60 mV to 80 mV for 100 ms , held at 40
mV for 500 ms, and then stepped down to 120 mV for 100 ms
before beginning the voltage ramp toþ20 mV for 500 ms. After the
ramp, the cells were held at 80 mV for 100 ms before resuming
to 60 mV holding potential. The protocol lasts for 1.5 s , including
sampling at the holding potential and repeated once every 5 s. For
analysis of outward current, wemeasured the current between40
mV and80 mV steps. Currents were recorded using Axopatch 200
(Molecular Devices, Sunnyvale, CA, USA) and analysed using
pClamp 10.2 software (Molecular Devices).Please cite this article as: P.D. Wright et al., Pranlukast is a novel small m
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Pranlukast was purchased from Sigma. Cinalukast, Montelukast,
MK-571, FPL-55712, SR-2640 purchased from Tocris. LY-171883
purchased from Cayman Chemical. Zaﬁrlukast purchased from
Selleck Chemicals. LA-TREK2-1, LA-TREK2-2 and LA-TREK2-3 were
synthesised at LifeArc. All compounds were dissolved in 100%
DMSO.
2.4. Statistics and analysis
For thallium ﬂux assays data are mean± standard deviation
(n 3 independent experiments) unless stated. Compound
response curves were iteratively ﬁtted to a four-parameter logistic
model using Graphpad Prism v7.01 (Graphpad, USA). For electro-
physiological experiments, data are expressed as mean values with
a range of 95% Conﬁdence Intervals. Statistical comparisons were
made using paired or unpaired t tests in Graphpad Prism 6.0. Ab-
solute P values are given where appropriate and differences were
considered signiﬁcant at the P 0.05 level.
3. Results
3.1. Development of a thallium-based assay to identify activators of
TREK2
Given the role of TREK2 in deﬁning excitability within the DRG,
it is likely that an activator of TREK2 would be therapeutically
beneﬁcial for the treatment of pain. We therefore sought to develop
a cell-based assay to identify small molecules which selectively
activate TREK2. Fluorescence-based thallium screens offer a way to
measure the activity of potassium channels in a high-throughput
manner. We have previously described the use of BacMam and
the importance of channel expression level in the identiﬁcation of
activators [21,23] and successfully used this approach to identify
novel activators of TRESK e Cloxyquin [23] and TASK3 e Terbina-
ﬁne [21].
Initially we sought to deﬁne the transduction parameters to
enable a system suitable for screening. Increasing amounts of
BacMam were added to U-2 OS cells and upon the addition of
thallium, the rate of increase in cellular ﬂuorescence then used as a
surrogate measure of channel activity. Fig. 1A conﬁrms that
increased BacMam correlated with increased channel function.
Additional parameters including dye loading conditions, thallium
concentration and cell number were also analysed to ensure
maximal assay performance (data not shown). To conﬁrm the
signal was TREK2 mediated, we investigated the pharmacology of
published [15,19,20] TREK2 modulators: BL-1249 (pEC50¼ 6.0
(±0.3)), GI-530159 (pEC50¼ 5.5 (±0.3)) and 11-deoxy prosta-
glandin F2a (pEC50¼ 5.3 (±0.2)) were all conﬁrmed as TREK2 ac-
tivators. In line with previous data [24] phorbol-12-myristate-13-
acetate (PMA) showed robust inhibition of the TREK2 signal
whilst TPA had no effect on channel activity (Fig. 1B). For the pur-
pose of potency determinations curve ﬁtting maxima asymptotes
were constrained for 11-deoxy prostaglandin F2a and GI-530159 as
appropriate.
A library of approximately 1000 structurally diverse small
molecule compounds was then screened to identify novel activa-
tors of TREK2. Activity was deﬁned relative to the PMA inhibited
wells (0%) and DMSO/vehicle containing wells (100%) and a small
number of compounds were identiﬁed that increased the rate of
ﬂuorescence >3 standards deviations above the control response.
Putative hits were re-screened against non-transduced cells to
remove assay interferers (compounds which increase ﬂuorescence
signal independent of TREK2). Pranlukast, a cysteinyl leukotrieneolecule activator of the two-pore domain potassium channel TREK2,
0.1016/j.bbrc.2019.09.093
Fig. 1. Development of a thallium ﬂux assay to measure TREK2 activity. (A) Titration of BacMam. As BacMam levels increase (%v/v present in media), there is an increase in the rate
of ﬂuorescence after the addition of thallium. This is proportional to increased TREK2 activity in the assay. (B) Pharmacology of TREK2 activators. Exemplar data showing activity of
BL-1249, 11-deoxy prostaglandin F2a (PGF-2a), GI-530159, PMA, Pranlukast and TPA. All data show rate of ﬂuorescence increases between 13 and 19 s, error bars denote S.E.M, n 2.
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with a pEC50 of 5.8 (±0.1), Fig. 1B. The magnitude of the Pranlukast
response was consistently lower than that of the putative TREK1
opener, BL-1249. The maximal rate of ﬂuorescence increase was 54
(±9) % of that observed with BL-1249. Our thallium ﬂux assay is
typically runwith a 30-min pre-incubation of compound before the
thallium addition. For Pranlukast we also ran our assay with no pre-
incubation i.e. thallium was added immediately after Pranlukast.
Using this paradigm, the magnitude of Pranlukast was nearly
identical to that of BL-1249 whilst the pEC50 remained consistent.
3.2. Selectivity and structure activity relationship studies of
Pranlukast
To investigate the selectivity of Pranlukast as an activator of
TREK2 we measured its pharmacology against a range of other K2P
channels. Thallium ﬂux assays were developed to allow proﬁling
against other members of the K2P superfamily (Table 1). No activity
could be observed against TASK3, TASK2 and THIK1. The activity
observed with TREK1 and TRESK highlights the difﬁculty in
comparing relative selectivity of activating molecules. Regarding
TREK1, a near identical pEC50 of 5.7 (±0.2) was observed for
Pranlukast. However, in order to account for differences between
each test system, e.g. how thallium ﬂux compares to channel ac-
tivity, it is perhaps better to compare the activity of Pranlukast toTable 1
Activity of Pranlukast, TREK tool compounds, Pranlukast analogues and CysLT1 antagonist
and rate of ﬂuorescence increase. Compounds were deﬁned as inactive where no curve
concentration used. All compounds screened n 4 independent experiments.
TREK1 TREK2 TRESK
Pranlukast Activator (pEC50¼ 5.7± 0.2) Activator (pEC50¼ 5.8± 0.1) Activator
BL-1249 Activator (pEC50¼ 6.6± 0.3) Activator (pEC50¼ 6.0± 0.3) Activator
GI-530159 Activator (pEC50¼ 6.7± 0.1) Activator (pEC50¼ 5.5± 0.3) Activator
PGF2a Inhibitor Activator (pEC50¼ 5.3± 0.2) Inactive
PMA Inhibitor Inhibitor Activator
Zaﬁrlukast Inhibitor Activator (pEC50< 5.0) Activator
Cinalukast Inactive Inactive Inactive
Montelukast Inhibitor Inactive Activator
MK-571 Inhibitor Inactive Inactive
FPL 55712 Inactive Inactive Inactive
SR 2640 Activator (pEC50< 5.0) Inactive Inactive
LY171883 Inhibitor Inactive Inactive
LA-TREK2-1 Activator (pEC50¼ 5.3± 0.2) Activator (pEC50< 5.0) Activator
LA-TREK2-2 Inactive Activator (pEC50< 5.0) Activator
LA-TREK2-3 Inactive Inactive Inactive
Please cite this article as: P.D. Wright et al., Pranlukast is a novel small m
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activity. As described above, both BL-1249 and GI-530159 are
shown to be active at TREK1 and TREK2. BL-1249 has been
described as displaying equal potency at both TREK1 and TREK2
[25]. Pranlukast is either equipotent (BL-1249) or more potent (GI-
530159) than these standards at TREK2 but is markedly less potent
than both at TREK1. It should also be noted that in our thallium ﬂux
assays BL-1249 is more active at TREK1 (pEC50¼ 6.6 (±0.3)) than
TREK2 (pEC50¼ 6.0 (±0.3)). In the absence of a native ligand it is
impossible to completely rationalize differences in Pranlukast ac-
tivity between TREK1 and TREK2 but the data is suggestive of
selectivity for TREK2 when compared to TREK1 and is in line with
observations that activity of activators is not easily compared by
pEC50/potency alone. At TRAAK Pranlukast displayed no signiﬁcant
activation (data not shown). Pranlukast showed a near identical
pEC50 of 5.6 (±0.2) at TRESK, however it was signiﬁcantly less
potent than other TRESK activators (PMA pEC50¼ 8.6 (±0.1)) and
showed a lower magnitude of response. This data highlights the
need to use multiple tool compounds when investigating native
channels responsible for a physiological response and that rank
order of potencies is important in the absence of compounds
showing complete selectivity.
To investigate structure activity relationships of Pranlukast’s
effects at TREK2 other commercially available CysLT1 receptor an-
tagonists were purchased and assayed (Table 1) based on thes at multiple K2P channels. All compounds were measured using thallium ﬂux assay
ﬁt was possible. Compounds listed as pEC50< 5.0 did not activate at 50% at the top
TASK-3 TASK2 THIK1 NT
(pEC50¼ 5.6± 0.2) Activator (pEC50< 5.0) Inactive Inactive Inactive
(pEC50¼ 5.5± 0.6) Inactive Inactive Inactive Inactive
(pEC50¼ 5.1± 0.6) Inactive Inactive Inactive Inactive
Inactive Inactive Inactive Inactive
(pEC50¼ 8.6± 0.1) Inactive Inactive Inactive Inactive
(pEC50 < 5.0) Activator (pEC50¼ 5.6± 0.1) ND ND ND
Activator (pEC50< 5.0) Inactive Inactive Inactive
(pEC50 < 5.0) Inactive ND ND ND
Inactive ND ND ND
Inactive Inactive Inactive Inactive
Inactive Inactive Inactive Inactive
Inactive ND ND ND
(pEC50 < 5.0) Inactive Inactive Inactive Inactive
(pEC50 < 5.0) Inactive Inactive Inactive Inactive
Inactive Inactive Inactive Inactive
olecule activator of the two-pore domain potassium channel TREK2,
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thereof, and if activity were observed, might be expected to bind at
a similar site to Pranlukast itself. A small number of close analogues
of Pranlukast were also designed and synthesised to complement
the commercial compounds. These were chosen to explore the
shortening or removal of the lipophilic carboxamide side chain (LA-
TREK2-1, LA-TREK2-2 and LA-TREK2-3), with a view to determining
minimal structural requirements for activity. Structures are shown
in supplementary material. None of the analogues tested showed
an increase in activity at TREK2 compared to Pranlukast. Only
Zaﬁrlukast, LA-TREK2-1, and LA-TREK2-2 retained any ability to
activate TREK2 and in each case at much lower potencies
(pEC50> 5). Interestingly, several analogues tested were inhibitors
of TREK1. Zaﬁrlukast was an inhibitor of TREK1 and an activator of
TREK2. Montelukast, LY171883, MK-571 were inhibitors of TREK1
but inactive at TREK2. This data was in line with previous obser-
vations suggesting very small changes to structures can have pro-
found effects on activity at K2P channels, and that compounds
within a chemical series can be activators or inhibitors.
3.3. Characterisation of Pranlukast on TREK channel currents using
whole-cell patch clamp electrophysiology
The effect of Pranlukast (3 mM) was investigated on WT TREK1
and TREK2 channel currents in whole-cell recordings. Exemplar
traces for each are shown in Fig. 2. Fig. 2A shows the time course for
activation of TREK1 by Pranlukast and Fig. 2B individual current
traces in the presence and absence of Pranlukast. Fig. 2C shows theFig. 2. A) Time course of enhancement of TREK1 wildtype (WT) current by Pranlukast (3 m
Pranlukast (3 mM) (red). (C) Time course of enhancement of TREK2 WT current by Pranluka
(3 mM) (red). Currents were evoked by the step-ramp voltage protocol, as detailed in the Me
referred to the Web version of this article.)
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dividual current traces in the presence and absence of the com-
pound. The combined data for all cells is shown in Fig. 3. For TREK2,
Pranlukast (3 mM) evoked a 228.6% [95% CI: 162.0e295.2, n¼ 30]
enhancement of current. The size of the current was signiﬁcantly
larger in the presence than absence of Pranlukast (p< 0.0001,
paired t-test, Fig. 3). For TREK1, a 66.4% [95% CI: 20.7e112.1, n¼ 17]
enhancement of current was observed with Pranlukast, which was
again signiﬁcant (p¼ 0.0093, paired t-test, Fig. 3). Importantly, the
degree of enhancement of TREK2 current by Pranlukast was
signiﬁcantly larger than that seen for TREK1 current (p¼ 0.0011, t-
test). In agreement with the thallium ﬂux data, this is highly sug-
gestive that Pranlukast shows a selective activation for TREK2
compared to TREK1.
Alternative translation initiation (ATI) gives rise to more than
one form of both TREK1 and TREK2 [26,27]. For TREK1 there are two
ATI-isoforms. The shorter form lacking 41 amino acids of the N
terminus [28]. This shorter form of TREK1 has different properties
compared to the longer form, with a smaller current density,
decreased potassium (K) selectivity and increased sensitivity to
some activators including FFA and BL-1249 [26,27]. In this study,
the current density for the short form of TREK1 was 2.7 pA/pF [95%
CI: 1.8e3.6, n¼ 10] compared to 32.8 pA/pF [95% CI: 25.4e40.1,
n¼ 26] for the longer form of TREK1. Activation of the short form of
TREK1 by Pranlukast was just 17.6% [95% CI: 24.4e59.7, n¼ 7] and
the current size was not signiﬁcantly different in the presence
compared to the absence of Pranlukast (p¼ 0.387, paired t-test,
Fig. 3). For TREK2, there are three isoforms [27] with variableM). (B) Currents recorded through TREK1 WT channels in control solution (black) and
st (3 mM). D) Currents recorded through TREK2 WT channels in (black) and Pranlukast
thods. (For interpretation of the references to colour in this ﬁgure legend, the reader is
olecule activator of the two-pore domain potassium channel TREK2,
0.1016/j.bbrc.2019.09.093
Fig. 3. Effect of Pranlukast (3 mM) on outward current (pA) measured as the difference
between at 40 and 80 mV for TREK1 WT, TREK2 WT and variants of TREK1 and
TREK2. Individual cell currents are shown before (red symbols) and after (blue sym-
bols) the application of Pranlukast. Mean data is shown by the box, and the error bars
represent 95% conﬁdence intervals. (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the Web version of this article.)
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not altered (unlike TREK1), they do show a differential single
channel conductance proﬁle and altered sensitivity to the inhibi-
tory compound carvedilol [27,29]. The current density for the short
form of TREK2was 21.6 pA/pF [95% CI: 16.5e26.7, n¼ 27] compared
to 41.6 pA/pF [95% CI: 31.7e51.5, n¼ 23] for the intermediate form
and 49.3 pA/pF [95% CI: 36.7e61.2, n¼ 23] for the full-length form
of TREK2. Activation of the short form of TREK2 by Pranlukast was
338.4% [95% CI: 240.9e435.9, n¼ 18], the intermediate form was
217.8% [95% CI: 160.0e275.6, n¼ 16] and the long form was 277.5%
[95% CI: 159.7e395.3, n¼ 17]. For each isoform, the size of current
was signiﬁcantly larger in the presence than absence of Pranlukast
(p< 0.0001 in each case, paired t tests, Fig. 3) and the degree of
enhancement was similar to WT TREK2 (Fig. 3).
From the crystal structure of TREK2 bound to the inhibitory
compound norﬂuoxetine, a number of amino acids (AA) were
identiﬁed as contact points for this compound including Leucine (L)
320 in the TM4 region [16]. The same AA on TREK1 has recently
been shown to contribute to the binding site for the activator BL-
1249 [30] and mutation of this AA has been shown to reduce the
effectiveness of both compounds. We therefore mutated this AA
(L320A) on TREK2 to determine, whether it contributed to the
effectiveness of Pranlukast. Activation of TREK2_L320A by Pranlu-
kast was 350.4% [95% CI: 129.4e571.5, n¼ 14], similar to that seen
for WT TREK2 channels. The size of current was signiﬁcantly larger
in the presence than absence of Pranlukast (p< 0.0001, paired t-
test, Fig. 3).
Two other pharmacological activators of TREK channels, ML335
andML402 have been shown to act asmolecular wedges to stabilise
the channel in an open conformation by binding to a novel cryptic
binding site [18]. Mutation of a lysine residue in TREK1, adjacent to
the selectivity ﬁlter of the channel, has been shown to abolish the
effect of these compounds. We mutated the equivalent residue inPlease cite this article as: P.D. Wright et al., Pranlukast is a novel small m
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occurring due to a similar mechanism. Activation of TREK2_K302Q
by Pranlukast was 257.3% [95% CI: 75.0e439.6, n¼ 13], again
similar to that seen for WT TREK2. The size of current was signiﬁ-
cantly larger in the presence than absence of Pranlukast
(p¼ 0.0037, paired t-test, Fig. 3).
This work conﬁrms that Pranlukast is an activator of TREK2 and
is suggestive it does not bind at either of the two described binding
sites. It is interesting to note that a subset of Pranlukast analogues
that are activators of TREK2 are inhibitors of TREK1. This is similar
to the mode of action seenwith 11-deoxy prostaglandin F2a, which
is suggested to act in a similar way to extracellular protons [20].
Whilst it is clear further work using the known variants of TREK2
will be required to identify a binding modality of Pranlukast, it
provides an interesting tool for further deﬁning the differentmodes
of activation described for TREK2.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.bbrc.2019.09.093.
Transparency document
Transparency document related to this article can be found
online at https://doi.org/10.1016/j.bbrc.2019.09.093.
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